Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025

Core Insights - Revelation Biosciences, Inc. reported financial results for the three and nine months ended September 30, 2025, highlighting significant corporate developments [1] Financial Performance - The company received gross proceeds of $9.6 million from warrant inducement in September 2025, indicating strong financial backing [1] Clinical Developments - Revelation announced groundbreaking top-line results from the PRIME Clinical Study, which are expected to advance the company's development phase [1] Leadership Commentary - CEO James Rolke emphasized that the outstanding PRIME data and subsequent financing validate the potential of Gemini, positioning the company on solid footing for future advancements [1]